{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:36:52Z","timestamp":1791992212755,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI036219"],"award-info":[{"award-number":["P30AI036219"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD028540"],"award-info":[{"award-number":["S10OD028540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10RR023461"],"award-info":[{"award-number":["S10RR023461"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jchromb.2023.123905","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:49:48Z","timestamp":1697392188000},"page":"123905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring"],"prefix":"10.1016","volume":"1230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-8837","authenticated-orcid":false,"suffix":"III","given":"Raymond E.","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Oberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-7037","authenticated-orcid":false,"given":"Sharon A.","family":"Riddler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4339-1382","authenticated-orcid":false,"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-3725","authenticated-orcid":false,"given":"Aaron S.","family":"Devanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123905_b0005","unstructured":"World Health Organization (WHO), HIV and AIDS Key Facts, (2023). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids (accessed April 18, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/hiv.12421","article-title":"Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis","volume":"18","author":"Teeraananchai","year":"2017","journal-title":"HIV Med."},{"key":"10.1016\/j.jchromb.2023.123905_b0015","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"HPTN 052 Study Team, Antiretroviral Therapy for the Prevention of HIV-1 Transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2023.123905_b0020","doi-asserted-by":"crossref","first-page":"e25408","DOI":"10.1002\/jia2.25408","article-title":"Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)","volume":"22","author":"Tolley","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jchromb.2023.123905_b0025","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","article-title":"Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research","volume":"17","author":"Cobb","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jchromb.2023.123905_b0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jchromb.2023.123905_b0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3389\/fmicb.2019.01227","article-title":"GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds","volume":"10","author":"Singh","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jchromb.2023.123905_b0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QCO.0000000000000896","article-title":"Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus","volume":"36","author":"Lee","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jchromb.2023.123905_b0045","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2023.123905_b0050","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jchromb.2023.123905_b0055","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"CAPELLA Study Investigators, Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2023.123905_b0060","unstructured":"Gilead Sciences, Inc., SUNLENCA package insert, (2022). https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf (accessed April 16, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0065","doi-asserted-by":"crossref","first-page":"1133407","DOI":"10.3389\/fmicb.2023.1133407","article-title":"Strategies to overcome HIV drug resistance-current and future perspectives","volume":"14","author":"Temereanca","year":"2023","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.jchromb.2023.123905_b0070","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV."},{"key":"10.1016\/j.jchromb.2023.123905_b0075","unstructured":"Food and Drug Administration, Bioanalytical Method Validation: Guidance for Industry, (2018). https:\/\/www.fda.gov\/media\/70858\/download (accessed April 14, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0080","unstructured":"N.A. Shaik, F. Bellanti, C. Comisar, M. Rhee, S. Girish, R. Palaparthy, R. Singh, Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration (Abstract 504), (2023). https:\/\/www.croiconference.org\/abstract\/population-pk-analysis-to-guide-dosing-window-following-lenacapavir-sc-administration\/ (accessed June 13, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0085","unstructured":"Food and Drug Administration - Center for Drug Evaluation and Research, Sunlenca (lenacapavir) Integrated Review, (2022). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215973,215974Orig1s000IntegratedR.pdf (accessed June 16, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0090","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV."},{"key":"10.1016\/j.jchromb.2023.123905_b0095","unstructured":"ClinicalTrials.gov, Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine\/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1), (2023). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04994509 (accessed April 16, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0100","unstructured":"ClinicalTrials.gov, Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2), (2023). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04925752 (accessed April 16, 2023)."},{"key":"10.1016\/j.jchromb.2023.123905_b0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/17425247.2022.2135699","article-title":"Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges","volume":"19","author":"Agrahari","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jchromb.2023.123905_b0110","unstructured":"S. Delany-Moretiwe, Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084, (2021)."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322300315X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322300315X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:11:34Z","timestamp":1761606694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157002322300315X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"alternative-id":["S157002322300315X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123905","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123905"}}